Abstract
AbstractPopulation analysis of pharmacokinetic data for five differing dosage forms and routes for dexamethasone and betamethasone in 48 healthy nonpregnant Indian women was performed that accounted for a partial and complex cross-over design. Single doses of 6 mg dexamethasone phosphate (DEX-P), betamethasone phosphate (BET-P), or 1:1 mixture of betamethasone phosphate and acetate (BET-PA) were administered orally (PO) or intramuscularly (IM). Plasma concentrations collected for two periods over 96 h were described with a two-compartment model with differing PO and IM first-order absorption inputs. Clearances and volumes were divided by the IM bioavailability $${F}_{IM}$$
F
IM
. The homogeneous ages, body weights, and ethnicity of the women obviated covariate analysis. Parameter estimates were obtained by the Laplace estimation method implemented in NONMEM 7.4. Typical values for dexamethasone were clearance ($${CL/F}_{IM})$$
C
L
/
F
IM
)
of 9.29 L/h, steady-state volume ($${{V}_{ss}/F}_{IM})$$
V
ss
/
F
IM
)
of 56.4 L, IM absorption constant $$\left({k}_{aIM}\right)$$
k
aIM
of 0.460 1/h and oral absorption constant ($${k}_{aPO})$$
k
aPO
)
of 0.936 1/h. Betamethasone parameters were CL/FIM of 5.95 L/h, $${Vss/F}_{IM}$$
V
s
s
/
F
IM
of 72.4 L, $${k}_{aIM}$$
k
aIM
of 0.971 1/h, and $${k}_{aPO}$$
k
aPO
of 1.21 1/h. The PO to IM F values were close to 1.0 for both drugs. The terminal half-lives averaged about 7.5 h for DEX, 17 h for BET, and 78 h for BET from BET-PA with the latter reflecting very slow release of BET from the acetate ester. Overall, BET exhibited slower clearance, larger volume of distribution, faster absorption, and longer persistence than DEX. These data may be useful in considering exposures when substituting one form of corticosteroid for another.
Funder
Bill and Melinda Gates Foundation
National Institute of General Medical Sciences
Publisher
Springer Science and Business Media LLC
Reference29 articles.
1. Committee Opinion No. 677 (2016) Antenatal corticosteroid therapy for fetal maturation. Obstet Gynecol 128:e187–e194. https://doi.org/10.1097/AOG.000000000001715
2. Roberts D, Brown J, Medley N, and Dalziel SR (2017). Antenatal corticosteroids for accelerating fetal lung maturation for women at risk of preterm birth. Cochrane Database Syst Rev 3: CD004454.
3. Raikkonen K, Gissler M, Kajantie E (2020) Associations between maternal antenatal corticosteroid treatment and mental and behavioral disorders in children. JAMA 323:1924–1933
4. World Health Organization (WHO). Recommendations on Interventions to Improve Preterm Birth Outcomes (WHO, Geneva, Austria, 2015)
5. Rohdewald P, Mollmann H, Barth J, Rehder J, Derendorf H (1987) Pharmacokinetics of dexamethasone and its phosphate ester. Biopharm Drug Dispos 8:205–212
Cited by
11 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献